Abstract
Folate deficiency has been associated with age-related neurodegeneration. One direct consequence of folate deficiency is a decline in the major methyl donor, S-adenosyl methionine (SAM). We demonstrate herein that pro-oxidant stress and dietary folate deficiency decreased levels of acetylcholine and impaired cognitive performance to various degrees in normal adult mice (9–12months of age, adult mice heterozygously lacking 5’,10’-methylene tetrahydrofolate reductase, homozygously lacking apolipoprotein E, or expressing human ApoE2, E3 or E4, and aged (2–2.5 year old) normal mice. Dietary supplementation with SAM in the absence of folate restored acetylcholine levels and cognitive performance to respective levels observed in the presence of folate. Increased aggressive behavior was observed among some but not all genotypes when maintained on the deficient diet, and was eliminated in all cases supplementation with SAM. Folate deficiency decreased levels of choline and N-methyl nicotinamine, while dietary supplementation with SAM increased methylation of nicotinamide to generate N-methyl nicotinamide and restored choline levels within brain tissue. Since N-methyl nicotinamide inhibits choline transport out of the central nervous system, and choline is utilized as an alternative methyl donor, these latter findings suggest that SAM may maintain acetylcholine levels in part by maintaining availability of choline. These findings suggest that dietary supplementation with SAM represents a useful therapeutic approach for age-related neurodegeneration which may augment pharmacological approaches to maintain acetylcholine levels, in particular during dietary or genetic compromise in folate usage.
This is a preview of subscription content, access via your institution.
References
Selhub J, Bagley LC, Miller J, Rosenberg JH (2000) B vitamins, homocysteine and neurocognitive function in the elderly. Am J Clin Nutr 71: 614S-620S.
MM and Shea TB (2003) Folate and Homocysteine in Neural Plasticity and Neurodegenerative Disorders. Trends in Neurosciences 26: 137–146.
Morrison, L.D. (1996) Brain S-adenosylmethionine levels are severely decreased in Alzheimer’s disease. J Neurochem. 67: 1328–1331.
Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D’Agostino BR, Wilson PW, Wolf PA (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. New Eng J Med 346: 476–483.
Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L and Mattson MP (2000) Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 20: 6920–6926.
Kruman II, Kumaravel TS, Lohani A Pedersen WA, Roy G. Cutler RG, Yuri Kruman, Norman Haughey N, Lee J, Michele Evans M and Mattson MP (2002) Folic Acid Deficiency and Homocysteine Impair DNA Repair in Hippocampal Neurons and Sensitize Them to Amyloid Toxicity in Experimental Models of Alzheimer’s Disease J. Neurosci. 22: 1752–1762.
Ho PI, Collins SC, Dhitavat S, Ortiz D, Ashline D, Rogers E, Shea TB. (2001) Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem. Jul;78(2): 249–53.
Ho PI, Ortiz D, Rogers E and Shea TB (2002) Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res: 70: 694–702.
Ho P, Ashline D, Dhitavat S, Collins S, Rogers E And Shea TB (2003). Folate Deprivation Induces Neurodegeneration: Roles Of Oxidative Stress And Increased Homocysteine. Neurobiol Dis 14: 32–42.
White AR, Huang X, Jobling MF, Barrow CJ, Beyreuther K, Masters CL, Bush AI, Cappai R (2001) Homocysteine potentiates copper-and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer’s-type neurodegenerative pathways. J Neurochem. 76: 1509–1520
Fuso A, Seminara L, Cavallaro RA, D’Anselmi F, Scarpa S (2005) S-adenosylmethionine/ homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci. 28: 195–204.
Scarpa S, Fuso A, D’Anselmi F and Cavallaro RA (2003) Presenilin 1 gene silencing by S-adenosylmethionine. FEBS Lett 541: 145–148
Kamboh MI. Apolipoprotein E polymorphism and susceptibility to Alzheimer’s disease. Hum Biol 2004; 67: 195–215.
Tchantchou F, Graves M, Ortiz D and Shea TB (2005a) S-adenosyl methionine: a link between nutritional and genetic risk factors in Alzheimer’s disease. J Nutri Health Aging: in press
Anello G, Gueant-Rodriguez RM, Bosco P, Gueant JL, Romano A, Namour B, Spada R, Caraci F, Pourie G, Daval JL and Ferri R (2004) Homocysteine an methylenetetrahydrofolate reductase polymorphism in Alzheimer’s disease. Neuroreport. 15: 859–861.
Regland B, Blennow K Germgard T, Koch-Schmidt AC, Gottfries CG. The role of the polymorphic genes apolipoprotein E and methylene-tetrahydrofolate reductase in the development of dementia of the Alzheimer type. Dement Geriatr Cogn Disord 1999; 10: 245–251.
Wang B, Jin F, Kan R, Ji S, Zhang C, Lu Z, Zheng C, Yang Z, Wang L (2005) Association of MTHFR gene polymorphism C677T with susceptibility to late-onset Alzheimer’s disease. J Mol Neurosci. 27: 23–27.
Bottiglieri T, Godfrey P, Flynn T, Carney MW, Toone BK, Reynolds EH (1990) Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry. 53: 1096–1098.
Kennedy BP, Bottiglieri T, Arning E, Ziegler MG, Hansen LA, Masliah E. (2004) Elevated S-adenosylhomocysteine in Alzheimer brain: influence on methyltransferases and cognitive function. J Neural Transm. 111: 547–111567
Mihalick SM, Ortiz D, Kumar R, Rogers E and Shea TB (2004) Folate and vitamin E deficiency impair cognitive performance in mice subjected to oxidative stress: differential impact on normal mice and mice lacking apolipoprotein E. Neuromol Med 4: 197–202.
Albert JE, Miscoulon D, Nierenberg AA, Fava M (2000) Nutrition and depression: focus on folate. Nutrition 16: 544–581.
Miscouloun D and Fava M (2002) Role of S-adenosyl-L-methionine in the treatment of depression:a review of the evidence Am J Clin Nutr 76: 1158S-61S.
Freeman GB, Gibson GE.(1988) Dopamine, acetylcholine, and glutamate interactions in aging. Behavioral and neurochemical correlates. Ann N Y Acad Sci. 515: 191–202.
Fu AL, Li Q, Dong ZH, Huang SJ, Wang YX, Sun MJ (2004) Alternative therapy of Alzheimer’s disease via supplementation with choline acetyltransferase. Neurosci Lett. 368: 258–262
Giacobini E.(2003) Cholinergic function and Alzheimer’s disease. Int J Geriatr Psychiatry. 18(Suppl 1): S1-S5
Shen ZX (2004) Brain cholinesterases: III. Future perspectives of AD research and clinical practice. Med Hypotheses. 63: 298–307.
Terry AV and Buccafusco JJ. (2003) The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development J Pharmacol Exp Ther. 306: 821–827.
Zeisel SH (2000). Choline: needed for normal development of memory. J Am Coll Nutr. 19: 528S-531S.
Zeisel SH (2000). Choline: an essential nutrient for humans. Nutrition. 16: 669–671.
Higgins JP, Flicker L (2003) Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev.3: CD001015.
McDaniel MA, Maier SF, Einstein GO. (2003) “Brain-specific” nutrients: a memory cure? Nutrition. 19: 955–956.
Kim, Y.-I., Miller, J. W., da Costa, K.-A., Nadeau, M., Smith, D., Selhub, J., Zeisel, S. H., Mason, J. B. (1994) Severe folate deficiency causes secondary depletion of choline and phosphocholine in rat liver. J. Nutr. 124: 2197–2203
Williams AC, Ramsden DB. (2005) Nicotinamide homeostasis: a xenobiotic pathway that is key to development and degenerative diseases. Med Hypotheses. 2005;65(2): 353–62.
Erb C and Klein J (1998) Enhancement of brain choline levels by nicotinamide: mechanism of action. Neurosci Letters. 249: 111–114.
Galletti P, De Rosa M, Nappi MA, Pontoni G, del Piano L, Salluzzo A, Zappia V. (1985) Transport and metabolism of double-labelled CDPcholine in mammalian tissues. Biochem Pharmacol. 1985 Dec 1;34(23): 4121–30.
Kohlmeier M, da Costa KA, Fischer LM, Zeisel SH (2005) Genetic variation of folate-mediated one-carbon transfer pathway predicts susceptibility to choline deficiency in humans. Proc Natl Acad Sci U S A. 102: 16025–16030.
Schwahn BC, Chen Z, Laryea MD, Wendel U, Lussier-Cacan S, Genest J Jr, Mar MH, Zeisel SH, Castro C, Garrow T and Rozen R (2003) Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency. FASEB J.:512–514.
Tchantchou F, Chan A, Kifle L, Ortiz D and Shea TB (2005b) Apple juice concentrate prevents oxidative damage and cognitive decline in aged mice. J Alz Dis: in press.
Chen, Z., Karaplis, A. C., Ackerman, S. L., Pogribny, I. P., Melnyk, S., Lussier-Cacan, S., Chen, M. F., Pai, A., John, S. W. M., Smith, R. S., et al. (2001) Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum. Mol. Genet 10, 433–443
Shea TB and Rogers E (2002) Folate quenches oxidative damage in brains of apolipoprotein E-deficient mice: augmentation by vitamin E. Mol Brain Res 108: 1–6.
Tchantchou F, Graves M, Ortiz D and Shea TB (2005a) S-adenosyl methionine: a link between nutritional and genetic risk factors in Alzheimer’s disease. J Nutri Health Aging: in press
Clark B, Halpern R, Smith R (1975) A fluorimetric methods for quantitation in the picamole range of N-Methylnicotinamide and Nicotinamide in serum. Anal Biochem. 68: 54–61.
Chisty M, Reichel A, Abbott NJ and Begley DJ (2002) S-adenosylmethionine is substrate for carrier-mediate transport at the blood-brain barrier in vitro. Brain Res 942: 46–50.
McCaddon A, Kelly C. Alzheimer’s disease: a cobalaminergic hypothesis. Med.Hypotheses 1992;37(3): 161–165.
Tchantchou F, Graves M, Ortiz D, Rogers E and Shea TB (2004) Dietary supplementation with 3-deaza adenosine, N-acetyl cysteine, and S-adenosyl methionine provide neuroprotection against multiple consequences of vitamin deficiency and oxidative challenge: relevance to age-related neurodegeneration. Neuromolecular Med. 2004;6(2–3): 93–103.
Smolkova B, Dusinska M, Raslova K, Barancokova M, Kazimirova A, Horska A, Supustova V and Collins A (2004) Folate levels determine effect of antioxidant supplementation on micronuclei in subjects with cardiovascular risk. Mutagenesis 19: 469–476.
Troen A (2005) The central nervous system in animal models of hyperhomocysteinemia. Prog Neuro-Psychopharm Biol Psychia 29: 1140–1151.
Albert JE, Miscoulon D, Nierenberg AA, Fava M (2000) Nutrition and depression: focus on folate. Nutrition 16: 544–581.
Miscouloun D and Fava M (2002) Role of S-adenosyl-L-methionine in the treatment of depression:a review of the evidence Am J Clin Nutr 76: 1158S-61S.
Ricceri L, Minghetti L, Moles A, Popoli P, Confaloni A, De Simone R, Piscopo P, Scattoni ML, di Luca M, Calamandrei G. (2004) Cognitive and neurological deficits induced by early and prolonged basal forebrain cholinergic hypofunction in rats. Exp Neurol. 189: 162–172
Carter J and Lippa CF (2001) Beta-amyloid, neuronal death and Alzheimer’s disease. Curr Mol Med. 1: 733–737.
Savonenko AV, Yu GM, Price DL, Borchelt DR and Markowska (2003) Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APPswe. Neurobiol Aging 12: 194–211.
Aucoin JS, Jiang P, Aznavour N, Tong XK, Buttini M, Descarries L, Hamel E. (2005) Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer’s disease. Neurosci 132: 73–86.
Spowart-Manning L, van der Staay FJ (2004) The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse. Behav Brain Res 151: 37–46.
Bottiglieri T, Hyland K, Reynolds EH. (1994) The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs 1994 Aug;48: 137–152.
Bressa GM (1994) S-adenosyl-L-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand 89: 7–14.
Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CP, Francis PT, Lasheras B, Ramirez MJ.(2005) Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer’s disease. Neuropsychologia. 43: 442–449.
Zarros ACh, Kalopita KS, Tsakiris ST(2005) Serotoninergic impairment and aggressive behavior in Alzheimer’s disease. Acta Neurobiol Exp. 65: 277–286
Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, Whalen E, Emir B; Donepezil MSAD Study Investigators Group. (2002) Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr. 14: 389–404.
Craig D, Hart DJ, McCool K, McIlroy SP, Passmore AP (2004) Apolipoprotein E e4 allele influences aggressive behaviour in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 75: 1327–1330.
Engelborghs S, Dermaut B, Marien P, Symons A, Vloeberghs E, Maertens K, Somers N, Goeman J, Rademakers R, Van den Broeck M, Pickut B, Cruts M, Van Broeckhoven C., De Deyn PP (2006) Dose dependent effect of APO epsilon4 on behavioral symptoms in frontal lobe dementia. Neurobiol Aging. 27: 285–292.
Ramassamy C., Averill D, Beffert L., Throux L., Lussier-Cacan S., Cohn J.S., Christen Y., Schoofs J. and Davignon J. (1999) Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer’s disease is related to the apolipoprotein E genotype. Free Rad Biol Med 27, 544–553.
Ramassamy C., Kryzwkowski P., Averill D., Lussier-Cacan S., Throux L., Christen Y., Davignon J. and Poirier J., (2001). Impact of apoE deficiency on oxidative insults and antioxidant levels in the brain. Mol. Brain Res. 86: 76–83
Crutcher KA. (2004) Apolipoprotein E is a prime suspect, not just an accomplice, in Alzheimer’s disease. J Mol Neurosci. 2004;23(3): 181–8.
Ashford JW (2004) APOE genotype effects on Alzheimer’s disease onset and epidemiology. J Mol Neurosci. 2004;23(3): 157–65.
Roses AD (1997) Apolipoprotein E: a gene with complex biological interactions in the aging brain. Neurobiol Dis 4: 170–185.
Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM and Holtzman DM (2002) Human and murine ApoE markedly influence Abeta metabolism both prior and subsequent to plaque formation in a mouse model of Alzheimer’s disease. Neurobiol Dis 9: 305–318.
Botto LD and Yang Q (2000) 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 151: 862–867.
Frosst P et al. (1995) Identification of a candidate genetic risk factor for vascular disease: a common mutation at the methylenetetrahydrofolate reductase locus. Nat Genet 10: 111–113.
Shields, D.C. et al., (1999) The “thermolabile” variant of methylenetetrahydrofolate reductase and neural tube defects: An evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother. Am J Hum Genet. 64, 1045–1055.
Arrula VR, von Zuben PM, Chaiparini LC, Annichino-Bizzachi JM, Costa FF (1997) The mutation Ala677-Val in the methylene tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thrombo Haemost 77: 818–821.
Reyes-Engel A, Munoz E, Gaitan MJ, Fabre E, Gallo M, Dieguez JL, Ruiz M, Morell M. (2002) Implications on human fertility of the 677C→T and 1298A→C polymorphisms of the MTHFR gene: consequences of a possible genetic selection. Mol Hum Reprod 8: 952–957.
Banerjee RV and Matthews RG (1990) Cobalamin-dependent methionine synthase. FASEB 4: 1450–1459
Djurhuus R, Svardal AM and Ueland PM (1989) Differential efffects on growth, homocysteine and related compounds of two inhibitors of S-adenosylhomocysteine catabolism. Cancer Res 49: 124–130.
Dayal S, Bottiglieri T, Arning E, Maeda N, Malinow MR, Sigmund CD, Heistad DD, Faraci FM, Lentz SR. (2001) Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine beta-synthase-deficient mice. Circ Res 88: 1203–1209.
Holtzman DM (2004) In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. Neurobiol Dis 23: 247–245.
Minkeviciene R, Banerjee P, Tanila H (2004) Memantine improves spatial learning in a transgenic mouse model of Alzheimer’s disease. J Pharmacol Exp Ther. 2004 Nov;311(2): 677–82
Popovic M, Caballero-Bleda M, Popovic N, Bokonjic D, Dobric S (1997) Neuroprotective effect of chronic verapamil treatment on cognitive and noncognitive deficits in an experimental Alzheimer’s disease in rats Int J Neurosci. 92: 79–93
Arsland D (1998) Drug treatment of emotional and cognitive dysfunction in dementia. Tidsskr Nor Laegeforen. 118: 560–565
Moran M, Walsh C, Lynch A, Coen RF, Coakley D, Lawlor BA (2004) Syndromes of behavioural and psychological symptoms in mild Alzheimer’s disease. Int J Geriatr Psychiatry. 19: 359–364.
Rainer MK, Masching AJ, Ertl MG, Kraxberger E, Haushofer M (2001) Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia. J Clin Psychiatry. 62: 894–900.
Russo-Neustadt A, Cotman CW (1997) Adrenergic receptors in Alzheimer’s disease brain: selective increases in the cerebella of aggressive patients. J Neurosci. 17: 5573–55780.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chan, A., Tchantchou, F., Graves, V. et al. Dietary and genetic compromise in folate availability reduces acetylcholine, cognitive performance and increases aggression: Critical role of S-adenosyl methionine. J Nutr Health Aging 12, 252–261 (2008). https://doi.org/10.1007/BF02982630
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02982630
Keywords
- Folate
- Homocysteine
- Folate Deficiency
- Acetylcholine Level
- Hitachi F2000 Fluorescent Spectrophotometer